Frontier Diagnostics LLC develops a technology platform, imaging mass spectrometry (IMS), that combines the spatial information of microscopy with the benefits of molecular testing to bring capabilities to anatomic pathology. This capability complements existing pathology by adding objective diagnostic and prognostic capabilities based on the molecular expression of tissue rather than tissue morphology alone. The firm will be launching its first melanoma assay, MelanoMap, in 2019, aimed at empowering pathologists to make more informed patient diagnosis.
